Among MM patients, the overall proportion of individuals with ex vivo detectable SARS-CoV-2-specific CD8+ T cells was significantly reduced compared to the HCs (6/13 [46%] in MM patients vs. 34/43 [79%] in HCs, p = 0.0213) (Figure 2A). This evidence concerns the gene CD8A and Miyoshi myopathy.